| 2024/08/16 16:05:35 | |
|---|---|
| Price | |
| 5.233 EUR | |
| Difference | -1.19% (-0.06) |
General attributes
| ISIN | CA0717341071 |
| Symbol | BHC |
| Exchange | Stuttgart |
| Currency | EUR |
| Sector | Other |
| Security type | Stock |
| Market cap (m) | 1,920 EUR |
| Benchmark | S&P/TSX 60 INDEX |
Market data
| Bid (Bid size) | 5.196 EUR (2,500) |
| Ask (Ask size) | 5.264 EUR (2,500) |
| Open | 5.205 EUR |
| High | 5.233 EUR |
| Low | 5.158 EUR |
| Close (prev. day) | 5.296 EUR |
| VWAP | - |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 5 |
| Last size | 0 |
Futures and Options
| Related Futures | 15 |
| Related Options | - |
PDF Downloads
| Company report: BAUSCH HEALTH COMPANIES INC. |  |
Add Benchmark:
Recent research
| Date | Headline | Download | |
| 2024/08/12 |
|
Global Equity Ratings |
|
| 2024/07/24 |
|
Global Equity Ratings |
|
| 2024/07/12 |
|
Global Equity Ratings |
|
| 2024/06/21 |
|
Global Equity Ratings |
|
| 2024/06/14 |
|
Global Equity Ratings |
|
| 2024/08/16 16:05:35 | |
|---|---|
| Price | |
| 5.233 EUR | |
| Difference | -1.19% (-0.06) |
General attributes
| ISIN | CA0717341071 |
| Symbol | BHC |
| Exchange | Stuttgart |
| Currency | EUR |
| Sector | Other |
| Security type | Stock |
| Market cap (m) | 1,920 EUR |
| Benchmark | S&P/TSX 60 INDEX |
Market data
| Bid (Bid size) | 5.196 EUR (2,500) |
| Ask (Ask size) | 5.264 EUR (2,500) |
| Open | 5.205 EUR |
| High | 5.233 EUR |
| Low | 5.158 EUR |
| Close (prev. day) | 5.296 EUR |
| VWAP | - |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 5 |
| Last size | 0 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | -32.77% | -29.64% | -77.06% |
| Perf (abs.) | -2.58 | -2.23 | -17.79 |
| Beta | 1.89 | 1.60 | 1.81 |
| Volatility | 55.52 | 49.00 | 70.94 |
Add Benchmark:
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 5.034 EUR (40) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 5.923 EUR (59) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 6.667 EUR (33) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 7.095 EUR (46) |
| YTD High | date | 9.826 EUR (2024/03/28) |
| YTD Low | date | 4.720 EUR (2024/08/08) |
| 52 Weeks High | date | 9.826 EUR (2024/03/28) |
| 52 Weeks Low | date | 4.720 EUR (2024/08/08) |
Arbitrage views
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Tradegate | 2024/08/16 | 12:26 | 5.302 EUR | 0.00 | 4 |
| Toronto Stock Exchange | 2024/08/16 | 16:08 | 7.90 CAD | 0.16 | 146 |
| Stuttgart | 2024/08/16 | 16:05 | 5.233 EUR | 0.00 | 5 |
| SIX Swiss Exchange | 2019/06/28 | 17:35 | 24.11 CHF | 0.00 | 1 |
| NYSE | 2024/08/16 | 16:08 | 5.7568 USD | 0.41 | 595 |
| Munich | 2024/08/16 | 08:08 | 5.158 EUR | 0.00 | 1 |
| Frankfurt | 2024/08/16 | 08:08 | 5.156 EUR | 0.00 | 1 |
| Duesseldorf | 2024/08/16 | 08:10 | 5.152 EUR | 0.00 | 1 |
| Berlin | 2024/08/16 | 08:08 | 5.158 EUR | 0.00 | 1 |
Company Logo
Contact Details
| BAUSCH HEALTH COS. INC. |
| - - |
| 2150 St. Elzéar Boulevard West - H7L 4A8 Laval |
| Telefon: +1-514-744-6792 |
| Fax: + |
| E-mail: - |
PDF Downloads
| Company report: BAUSCH HEALTH COMPANIES INC. | |
Company Profile
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada. |
Members of Management Board
| Thomas Appio | Chairman of Managing Board |
| Tage Ramakrishna | Member of Executive Committee |
| Cees Heiman | Member of Executive Committee |
| Fernando Zarate | Member of Executive Committee |
| Graham Jackson | Member of Executive Committee |
| Jeff Hartness | Member of Executive Committee |
| Kathleen Fitzpatrick | Member of Executive Committee |
| Mirza Dautbegovic | Member of Executive Committee |
| Seana Carson | Member of Executive Committee |
| Tom Vadaketh | Member of Executive Committee |
Board of directors
| John Paulson | Chairman of Supervisory Board |
| Amy Wechsler | Member of Supervisory Board |
| Richard Mulligan | Member of Supervisory Board |
| Brett Icahn | Member of Supervisory Board |
| Christian Garcia | Member of Supervisory Board |
| Frank Lee | Member of Supervisory Board |
| Robert Power | Member of Supervisory Board |
| Sarah Kavanagh | Member of Supervisory Board |
| Steven Miller | Member of Supervisory Board |